Literature DB >> 22154594

Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms.

Hiroyoshi Takeuchi1, Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura.   

Abstract

OBJECTIVE: Antipsychotic treatment strategy for the maintenance phase of schizophrenia has been inconsistent in the literature. The purpose of this systematic review is to overview recommendations in various guidelines and algorithms.
METHODS: The guidelines and algorithms for schizophrenia that were published or updated in English after 2000 were searched, using Medline, PubMed, EMBASE, and PsycINFO with the following key words: guideline, algorithm, schizophrenia, and psychosis (last search: July 2011). The reference lists of the relevant reports were also examined.
RESULTS: Fourteen guidelines and algorithms were identified; only five of them clearly defined terms about the maintenance phase and treatment. Ten of 11 guidelines and algorithms did not recommend discontinuation of antipsychotics within five years; six of them partially recommended antipsychotic discontinuation for patients with first-episode schizophrenia exclusive. All nine guidelines and algorithms that referred to intermittent or targeted antipsychotic strategy endorsed against this strategy. Although being a hot topic of controversy, dose reduction of antipsychotics or lower dose therapy in the maintenance phase compared to the acute dosage is not recommended on the whole concerning atypical antipsychotics, whereas dose reduction appears sometimes considered acceptable for typical antipsychotics.
CONCLUSION: What constitutes maintenance phase and its treatment in schizophrenia has not yet been established in the literature. While discontinuation and intermittent or targeted strategies are not generally recommended, there is controversy regarding dose reduction or lower dose therapy, especially with regards to atypical antipsychotics. Further evidence is needed in order to derive treatment recommendations on antipsychotics in this critical treatment phase of schizophrenia.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154594     DOI: 10.1016/j.schres.2011.11.021

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  27 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 2.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

Review 3.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

4.  Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia.

Authors:  Qi Miao; Chengcheng Pu; Zhijiang Wang; Chao-Gan Yan; Chuan Shi; Qingjiu Cao; Xijin Wang; Zhang Cheng; Xue Han; Lei Yang; Yunyao Lai; Yanbo Yuan; Hong Ma; Keqing Li; Nan Hong; Xin Yu
Journal:  Can J Psychiatry       Date:  2020-02-06       Impact factor: 4.356

5.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

Review 6.  Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Authors:  Chen-Chung Liu; Hiroyoshi Takeuchi
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

7.  Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Authors:  Hideaki Tani; Shotaro Takasu; Hiroyuki Uchida; Takefumi Suzuki; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  Neuropsychopharmacology       Date:  2019-11-26       Impact factor: 7.853

8.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

9.  Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study.

Authors:  L Malandain; M Leygues; F Thibaut
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-22       Impact factor: 5.270

Review 10.  Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells.

Authors:  Bradley Watmuff; Shaunna S Berkovitch; Joanne H Huang; Jonathan Iaconelli; Steven Toffel; Rakesh Karmacharya
Journal:  Mol Cell Neurosci       Date:  2016-01-14       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.